Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bacterial Conjunctivitis
Inspire Pharmaceuticals Launches AzaSite in the United States for Ocular Infections
August 31st, 2007
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the U.S. launch and commercial availability of AzaSite(TM)(azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis. AzaSite has been shipped to pharmacies throughout the United States and Inspire's sales force of 98 sales representatives has begun product education outreach to physicians. AzaSite offers the fewest number of doses for the treatment of bacterial conjunctivitis, commonly called "pinkeye." The recommended dose for AzaSite is one drop twice-a-day for two days, followed by one drop once-a-day for the next five days, for a total of nine drops per affected eye. The current market...
Source: Drug Week (2007-08-31)
|
